Background: Plasmodium vivax circumsporozoite (PvCS) protein is a major sporozoite surface antigen involved in parasite invasion of hepatocytes and is currently being considered as vaccine candidate. PvCS contains a dimorphic central repetitive fragment flanked by conserved regions that contain functional domains. Methods: We have developed a chimeric 137-mer synthetic polypeptide (PvCS-NRC) that includes the conserved region I and region II-plus and the two natural repeat variants known as VK210 and VK247. The antigenicity of PvCS-NRC was tested using human sera from PNG and Colombia endemic areas and its immunogenicity was confirmed in mice with different genetic backgrounds, the polypeptide formulated either in Alum or GLA-SE adjuvants was assessed in inbred C3H, CB6F1 and outbred ICR mice, whereas a formulation in Montanide ISA51 was tested in C3H mice. Results: Antigenicity studies indicated that the chimeric peptide is recognized by a high proportion (60-70%) of residents of malaria-endemic areas. Peptides formulated with either GLA-SE or Montanide ISA51 adjuvants induced stronger antibody responses as compared with the Alum formulation. Sera from immunized mice as well as antigen-specific affinity purified human IgG antibodies reacted with sporozoite preparations in immunofluorescence and Western blot assays, and displayed strong in vitro inhibition of sporozoite invasion (ISI) into hepatoma cells. Conclusions: The polypeptide was recognized at high prevalence when tested against naturally induced human antibodies and was able to induce significant immunogenicity in mice. Additionally, specific antibodies were able to recognize sporozoites and were able to block sporozoite invasion in vitro. Further evaluation of this chimeric protein construct in preclinical phase e.g. in Aotus monkeys in order to assess the humoral and cellular immune responses as well as protective efficacy against parasite challenge of the vaccine candidate must be conducted.
Introduction
Plasmodium vivax, the second most important Plasmodium species in terms of epidemiological significance, causes ∼70-80 million clinical cases of malaria annually with 2.85 billion people living at risk of infection [1] . Although this parasite has been considered benign, during the last decade lethal P. vivax malaria cases have been documented [2, 3] and chloroquine-resistant strains have recently emerged [4, 5] . Furthermore, this parasite species produce hypnozoites forms that upon periodic reactivation induce clinical relapses, even in individuals who have emigrated from endemic regions.
During the last 2-3 decades, significant efforts have been invested in the development of Plasmodium falciparum subunit vaccines [6] [7] [8] and currently the RTS,S construct based on the P. falciparum circumsporozoite (CS) protein is the most advanced malaria vaccine candidate [9] . The CS protein is abundantly expressed on the sporozoite (spz) surface of all Plasmodium species. It is one of the antigens that is predominantly recognized by sera of individuals rendered immune after vaccination with irradiated spz [10] , and by individuals from endemic areas who have developed clinical immunity [11, 12] . In P. vivax, the central repeat domain (90-261 aa) is composed of 19 blocks of 9 amino acids each, with two allelic forms circulating in nature: the VK210 or common type (GDRADGQPA) [13] and the VK247 or variant type (ANGAGNQPG) [14] . Flanking regions contain small stretches of highly conserved sequences designated as region I (85-89 aa) and region II-plus (338-355 aa) that represent ligand domains for invasion of hepatocytes [15, 16] .
It has been shown that the CS protein is proteolytically cleaved at region I (RI) [17, 18] , and that this processing is required for parasite invasion. Antibodies to RI as well as those against the repeat region are able to block the cleavage process [15, 17] , thus, an effective vaccine targeting the CS protein must be able to elicit antibodies specific to the RI as well as to the two repeats variants regions.
During the last decade, the P. vivax CS (PvCS) has been extensively characterized [19] [20] [21] , and both preclinical studies and Phase 1 clinical trials using long synthetic peptides (LSP) corresponding to the N, R and C regions of the protein have indicated its potential as a vaccine candidate [22] [23] [24] [25] . In addition, a recombinant chimeric PvCS construct containing both the VK210 and the VK247 repeat variants was recently produced in Escherichia coli and its immunogenicity tested in mice. Different formulations of the construct were found to elicit antibodies that agglutinated live sporozoites [26, 27] .
Herein, we describe studies on novel formulations of the chimeric PvCS-NRC synthetic vaccine containing critical epitopes in a single construct joined together by the non-immunogenic modified diethylene glycol linker (DEG), selection of fragments was based on previous studies on the characterization of the PvCS protein (identification of B, CD4+, CD8+ epitopes) and on the immunogenicity of a pools of individuals peptides tested in mice, monkeys and humans [19] [20] [21] [22] [23] [24] [25] .
Materials and methods

Vaccine
The polypeptide PvCS-NRC was synthesized using solid-phase fluorenylmethoxycarbonyl (F-moc) chemistry [28] . Pseudoproline (oxazolidine) dipeptides were introduced at critical points in the Cterminal region and DEG (Merck Chemicals Ltd., Nottingham, UK) was inserted between the three fragments RI+VK210, RI+VK247 and C (Fig. 1A) . Pre-purified tertiary-butylthiolated precursors were oxidized and folded in solution accordingly [29] . The resulting construct was HPLC-purified and the purity (>85%) confirmed by analytic C18 HPLC (Fig. 1B ) and mass spectrometry (Fig. 1C ) (MALDI-TOF; Applied Biosystem). A polypeptide model was built using the INSIGHT II program (Accelrys, San Diego) [30] (Fig. 1D) .
Additionally, seven 20-aa long synthetic peptides identified as B-cell and T-helper (Th) epitopes located in the N-terminal (p8, p9 and p40) and central repeat (p10, p11, p32 and p43) regions of the P. vivax CS protein, and a LSP representing the carboxyl-terminal region (301-372 aa) designated as C-peptide, were synthesized and used to characterize antibody responses.
Human sera
Human serum samples of adults from malaria-endemic areas of Colombia and Papua New Guinea (PNG) as well as from a non-endemic area (Switzerland) were used to assess peptide antigenicity. PNG sera (n = 42) were collected in a cross-sectional study carried out in a highly malaria-endemic region of Maprik District, East Sepik Province [31] . The Colombian samples (n = 32) were obtained in the Buenaventura region where P. vivax is endemic with a constant low level of transmission [32] . Ethical clearance was obtained from the PNG Medical Research Advisory Committee as well as from the IRB of the Malaria Vaccine and Drug Development Center (MVDC) in Colombia. Negative control samples were obtained from Swiss adult donors with no malaria history and no previous travel to malaria-endemic areas and used as control in ELISA and IFA test.
Immunogenicity studies in mice
Groups of five mice corresponding to two syngeneic strains (C3H, CB6F1) and a group of seven outbred mice (ICR) were injected with PvCS-NRC formulated in alhydrogel (1 mg/mouse) and GLA-SE (20 g/mouse) [33, 34] , respectively, whereas a Montanide ISA51 (Seppic Inc., Paris, France) formulation was assessed in C3H mice according to manufacturer's recommendations. All mice were injected subcutaneously with 20 g of peptide in 50 L volume at the base of the tail on days 0, 20 and 40. Animals care was performed in accordance with institutional guidelines.
Humoral immune response
Antibody responses to PvCS-NRC as well as to the other peptides in mice and human were measured by ELISA; PvCS-NRC was used at 1 g/mL, whereas the constituent peptides were used at 5 g/mL, and the ELISA performed as described previously [19] . Additionally, parasite recognition by anti-peptide antibodies was determined by IFAT using P. vivax sporozoites as described previously [35] . Cutoff points for ELISA were calculated as three SD above the mean absorbance value at 405 nm of normal mouse sera or from healthy volunteers who had never been exposed to malaria. IFAT antibody titers were determined as the reciprocal of the end-point dilution that showed positive fluorescence [23] .
Reactivity of affinity-purified human antibodies
Reactivity of purified human antibodies with the polypeptide as well as the different constituents was determined by ELISA competition assay, using PvCS-NRC (1 g/mL) as the antigen substrate. Human IgG specific to PvCS-NRC were purified from pooled sera (50 mL) obtained from adults living in malaria-endemic areas of PNG as described previously [36] . The affinity-purified antibodies to PvCS-NRC were incubated 30 min at room temperature together with the constituent polypeptides (RI, VK210, VK247 or C) prior to adding to the peptide-coated ELISA plates. Reactivity of the adsorbed antibody preparations was then determined as described elsewhere (Section 2.6).
Western blot analysis
Protein extracts from lysed P. vivax sporozoites were separated on 12% SDS-polyacrylamide gel and electro-transferred to nitrocellulose (0.2 mm, Whatman Schleicher + Schuell, Florham Park, NJ) under cooling conditions overnight at 30 V. The membrane was blocked at room temperature, incubated with the primary antibody solution (purified IgG or sera from immunized mice), washed and incubated with an alkaline phosphatase-conjugated goat antimouse or anti-human IgG (1:1000, Sigma) [37] . Bound antibodies were visualized using BSIP/NBT substrate.
Inhibition of sporozoite invasion (ISI) assay
Affinity-purified human IgG antibodies specific to PvCS-NRC as well as sera of immunized mice were tested for the capacity to inhibit P. vivax sporozoite invasion of HepG2-A16 hepatoma-cells in vitro as described previously [22] . After size exclusion chromatography pre-purified (G75) samples were subject to folding of Cys(StBu) induced by a 100-fold molar excess of cysteine at 37
• C, pH 7.2, for 24 h. The main impurity corresponds to an incomplete oxidation of one 1 Stbu (m/z: 15145). The peak at m/z 15278 corresponds to the sinapinic acid addition product generated by the laser treatment of the sample during the mass spectrometry analysis. (C) HPLC chromatogram of PvCS-NRC. (D) Structural model of peptide PvCS-NRC. The N-terminal half of the peptide that includes two RI regions (red) and DEG cross-linkers (orange) is unfolded [49] while the C-terminal half form globular structure that was modeled by using the crystal structure of the homologous domain from P. falciparum (pdb code 3VDJ) [50] . The RII region is shown in blue.
Statistical analysis
Main experimental comparisons involved analysis of differences between adjuvants and strains of mice. Antibody titers were compared among adjuvants and strains of mice and a descriptive analysis was performed to evaluate trends in humoral immune responses within each group of mice. Additionally, the Mann-Whitney test was performed with OD data obtained after the third immunization to compare the antibody response of different groups of adjuvants, and the Kruskal-Wallis test was used to compare different strains of mice. Non-parametric p values ≤0.05 were considered statistically significant. Finally, the capacity to inhibit P. vivax sporozoite invasion of HepG2-A16 hepatoma-cells in vitro was compared between adjuvants in the different strains of mice using the Mann-Whitney test. Table 1 shows the prevalence of seropositive reactivity using serum samples from PNG and Colombia endemic areas, tested against PvCS-NRC and other CS fragments. In general, all polypeptides used in this study were more frequently recognized by PNG Table 1 Prevalence of antibodies to PvCS derived synthetic peptides in donors from Colombian and PNG. Peptide sera than by Colombian sera. More than 65% of adult donors from PNG and 58% Colombian adults recognized the PvCS-NRC antigen. Additionally, most of the polypeptide fragments were also recognized by up to 76% of PNG samples and up to 44% of Colombian samples (Table 1) . Peptides P9 and P40, containing the PvCS-RI region, were the epitopes most frequently recognized by Colombian sera (44%); whereas PNG sera were most reactive to P8 and P10 peptides (76%). The prevalence of antibodies specific for P11 and P32 peptides corresponding to the two repeat variants (VK210 and VK247, respectively) were also higher in PNG (>65%) with similar frequency of recognition within the same region (Table 1) . Finally, the C-terminus was recognized by 59% and 30% of PNG and Colombian sera, respectively.
Results
Antigenic recognition
Reactivity of purified IgG antibodies
Reactivity and specificity of the affinity-purified IgG were confirmed by ELISA and IFA tests. Antibodies showed reactivity to PvCS-NRC by ELISA at dilutions to 0.1 g/mL, and recognized the native protein on P. vivax sporozoites by IFAT at a concentration of 16 g/mL. Moreover, anti-PvCS-NRC antibodies recognized each of the individual constituent fragments by ELISA inhibition assay; antibodies reacted mainly with RI and C-regions followed by both VK210 and VK247 repeat regions ( Fig. 2A) . Finally, Western blot analysis of specific anti-PvCS-NRC purified antibodies recognized a double band at approximately 50 kDa typical of the CS protein (Fig. 2B ).
Immunogenicity in mice
Antibody titers were determined in all inbred and outbred immunized mice (Table 2) . Stronger antibody titers were generally observed when the polypeptide was formulated in GLA-SE and Montanide ISA51 than in Alum (p = 0.0001). Moreover, antibody responses were more consistent for the GLA-SE vaccine formulation, while high variability in number of responders and antibody titers was observed for mice inoculated with the Alum formulation. Although differences in response to PvCS-NRC formulated in GLA-SE or Alum were observed between the different strains of mice (Table 2) , no significant differences were observed among the two syngeneic (C3H, CB6F1) strains and the outbred (ICR) strain (p = 0.220).
CB6F1 and ICR mouse strains showed higher ELISA antibody titers, ranging from 6.5 × 10 5 to 5.9 × 10 6 , when they were immunized with the PvCS-NRC formulated in GLA-SE. In both cases seroconversion was detected after the second immunization, with boosting observed after the third immunization (Fig. 3) . In the case of C3H mice, ELISA titers were highly variable, ranging from 8.1 × 10 3 to 1.9 × 10 6 , with the exception of one animal that required three vaccine doses before seroconversion, all other mice seroconverted after the second immunization. Regarding PvCS-NRC-Alum formulations, most of the animals seroconverted with the second immunization dose, yet others required the third dose to seroconvert. The highest response was observed in the CB6F1 strain of mice with ELISA titers ranging between 3.0 × 10 2 and 6.6 × 10 5 , whereas the lowest response was shown in ICR and C3H mouse strains with ELISA titers ranging between 9.0 × 10 2 and 7.2 × 10 4 , and 3.0 × 10 2 and 8.1 × 10 3 , respectively (Fig. 3) .
Similar to GLA-SE, the PvCS-NRC polypeptide formulated in Montanide ISA 51 induced potent antibody responses in C3H mice with average ELISA titers between 6.6 × 10 5 and 5.9 × 10 6 and all mice seroconverted after the second immunization (Fig. 3) .
Antibodies to PvCS-NRC recognized the entire polypeptide and the individual peptide fragments, although some variability was observed depending on the adjuvant or mouse strain used (Fig. 4A) . In general, the C-terminal fragment and the RI-containing peptide Fig. 2 . Antibodies reactivity. (A) ELISA competition assay using anti-human specific purified antibodies to PvCS-NRC. Human affinity-purified antibodies to PvCS-NRC were incubated together with the constituent polypeptides (RI, VK210, VK247 or C) at serial dilutions starting at 1 mg/mL and the reaction incubated for 30 min at room temperature, prior their addition to the ELISA peptide-coated plates. (B) Immunoblot assays: lysed P. vivax sporozoites electrophoresed under non-reducing conditions were probed with affinity-purified human ␣-PvCS-NRC or antibodies produced in mice at 1:100 dilution. Relative size standards are indicated on the left in kDa. As negative control non-specific human purified antibodies from Swiss donors or sera of mice immunized with a P. falciparum erythrocytic antigen formulated in GLA-SE [46] and the homologous in P. vivax in Montanide were used. As a positive control a pool of serum samples from adults immunized with a mixture of PvCS LSP in a Phase 1b clinical trial were used [25] .
(P9) were the most frequently recognized, followed by the VK210 repeat. The VK247 repeat was recognized only by sera of mice immunized with PvCS-NRC formulated in GLA-SE.
All immunized mice recognized P. vivax sporozoites by IFA, regardless of the adjuvant used, albeit at different antibody titers (Fig. 4B) . Higher responses were observed in CB6F1 and ICR mice immunized with the GLA-SE formulation (IFA titers: 1:10,240), followed by responses in sera of C3H mice immunized with the Montanide ISA51 formulation (IFA titers: 1:5000), and then by sera of CB6F1 mice immunized with Alum (IFA titer: 1:1280).
Finally, Western blot analysis of the anti-PvCS-NRC pool of sera corresponding to C3H mice immunized with Montanide, and ICR and CB6F1 mice with GLA-SE formulation or Alum formulation recognized two bands at approximately 50 kDa and ∼15 kDa (Fig. 2B) , while no response was observed with serum pool of C3H mice immunized with PvCS-NRC formulated in GLA-SE or Alum.
Inhibition of sporozoite invasion (ISI) assay
Functional activity of specific PvCS-NRC-purified human antibodies and of whole antisera obtained after the third immunization was tested in ISI assays to determine the capacity of antipeptide antibodies to inhibit P. vivax sporozoite invasion of human hepatoma-cells (HepG2À-16) in vitro. Human antibodies to the entire PvCS-NRC polypeptide resulted in inhibitory activity up to 70%. Likewise, mouse sera produced strong inhibition (>65%), although the strongest inhibition (>75%) was observed in sera of mice immunized with PvCS-NRC formulated in GLA-SE. No significant differences were observed among the different adjuvant groups (p = 0.08) (Fig. 4C ).
Discussion
In the process of developing a pre-erythrocytic P. vivax vaccine for human use, we have developed a chimeric LSP derived from the P. vivax CS protein which includes an N-fragment-containing region I; the two repeat variants found in nature (VK210 and VK247); and the C fragment, all considered to play an important functional roles in sporozoite invasion of hepatocytes [15, 17] . It is encouraging that the chimeric polypeptide construct, named PvCS-NRC, and its individual peptides, were widely recognized by sera of individuals naturally exposed to malaria and additionally induced significant response in immunized mice. Of particular interest antibodies elicited recognized the protein on sporozoites and blocked sporozoite invasion in vitro.
All CS protein fragments studied were recognized by ELISA when tested with sera collected from both PNG and Colombian donors although, as expected each one was recognized with different frequencies, most likely due to the varying P. vivax endemicity in the respective countries [38, 39] . Although, in some cases the response to individual peptides seem to be greater than the full construct, especially for PNG samples, it is not possible to compare the additive or synergistic response since the amount of antigen used to test the PvCS-NRC and their corresponding antigens was different. As previously shown [19] , peptides corresponding to Nterminal flanking regions as well as to the repeat regions were more frequently recognized by human sera than that corresponding to the C-region. In fact, under natural conditions, the C-region appears to be masked by the N-fragment of the protein, and therefore it may be less exposed to the immune system [17] . However, in previous studies we have observed that even when peptides containing nearly complete N and C regions when administered Antibody titers are expressed in log10 of immune sera determined as the last dilution with an OD higher than that of the control serum + 3SD. The induced antibody responses were measured by ELISA ten days after second and third immunizations. ELISA was performed using threefold serial dilutions of the sera, starting from 1:100 to 1: 1.7 × 10 7 . Results were considered positive when absorbance of the test sera was greater than or equal to the mean value of control sera + 3SD. Normal mice sera samples obtained from naïve mice were used as control sera at 1:200 dilution.
independently, the N-fragment is more immunogenic in monkeys and humans than the C-fragment, with the latter more immunogenic in mice [22] . This observation is a critical consideration for human use vaccines development.
Herein, although PvCS-NRC displayed varying immunogenicity depending on the different vaccine formulations, reactivity of all formulations in both inbred and outbred mouse strains confirms the presence of multiple T-cell epitopes along the entire length of PvCS-NRC. Regarding helper efficiency, C and RI regions were the most frequently recognized by specific PvCS-NRC antibodies.
The lower immunogenicity of VK247 peptide is noteworthy; however we had also found that in endemic Colombian regions where VK247 is the prevalent phenotype [40] , antibodies to VK210 were more frequent than those to VK247, probably indicating its greater immunogenicity [41] .
It was interesting to confirm that purified human IgG specific to the polypeptide recognized the individual epitopes comprised in PvCS-NRC in ELISA, and were reactive to parasite in IFA and Western blot. Even more meaningful was the capacity displayed by the specific anti-PvCS-NRC antibodies to inhibit sporozoite 4 P. vivax sporozoites were used. A 100 g/mL purified IgG antibodies or 1:20 dilution of sera from mice immunized were added to each well. Percentages of inhibition are shown as the mean ± SD of duplicate wells. Each experiment was performed twice with similar results. Percentage of invasion inhibition was calculated by the formula: ([mean schizont number of negative control − mean schizont number of sample/mean schizont number of negative control] × 100). Negative control was normal mouse sera or Colombian normal human sera from naïve donors. Percentage of invasion inhibition was compared between GLA-SE and Alum adjuvants in the different strains of mice using the Mann-Whitney test p values ≤0.05 were considered significant. invasion in vitro. This might be associated with the significant clinical immunity observed in PNG [31] . Likewise, sera of immunized mice were also reactive by ELISA, IFA and WB and induced ISI >65%, and appeared to be associated with the adjuvant used, with GLA-SE and Montanide performing better than Alum. However, in terms of functional antibodies activity, no significant difference was observed among the three groups.
These results stress the complexity of adjuvants. While Alum is most commonly used with human vaccines [42] , it has not been found successful against malaria since such vaccines induce Th2 responses that are poorly effective against malaria parasites where protection is mainly mediated by Th1 responses. Here, one of the mouse stains displayed a strong but variable antibody response when the polypeptide was formulated in Alum. In general, in this study PvCS-NRC formulated in adjuvants Montanide ISA51 and GLA-SE induced strong antibody responses in most mouse strains tested. Immunogenicity of peptides formulated in Montanide ISA720 and ISA51 has been determined in previous studies on CS-LSP in Aotus monkeys [22, 24] and human volunteers [23, 25] . These formulations have been shown to be safe, well tolerated and immunogenic. However in other studies, Montanide formulations have been reported to induce reactogenicity as well as stability and reproducibility problems among different formulation batches [43] [44] [45] .
We proposed to use a Glucopyranosyl lipid A stable oil-in-water emulsion (GLA-SE) previously shown to produce strong cellular and/or humoral immune responses in animal models [26, 33, 34, 46] . In the present study, GLA-SE formulations induced the strongest humoral responses in both inbred and outbred mice, and antibodies obtained from immunized mice appeared to induce the strongest in vitro inhibition of sporozoite invasion, although no significant differences were observed regarding the formulation used. The GLA-SE formulation also induced antibodies that recognized all epitopes in the PvCS-NRC polypeptide, including reactivity with the two repeat variants, and being the only groups of mice that recognized VK247 variant.
Antibodies obtained by immunization with the polypeptide formulated in all tested adjuvants recognized the native protein in IFAT and Western blot regarding to the strain used. Three main bands were observed, two bands at approximately 50 kDa are typical of the CS protein [47] , whereas the band at 15 kDa could correspond to fragments of the processed CS protein.
This study confirms that the use of synthetic peptides represents a promising strategy for vaccine development. LSPs with lengths >100 amino acids can now be routinely and reproducibly synthesized [48] . Since for liver stage antigens where elicitation of a specific T-cell response is needed and linear peptides of limited length are required we argue that short peptides containing specific T-cell and B-cell epitopes inserted co-linearly into a long peptide chain with interposed non-immunogenic spacers to minimize the neo-epitopes formation could be enough to induce a protective immune response directed to the protein [37] . In conclusion, given the encouraging results obtained in this study, further studies are warranted for evaluation of PvCS-NRC as a potential vaccine candidate.
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